Completed OBSERVATIONAL NCT00916474

Virology Follow up Study in Subjects Previously Treated With Telaprevir

EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies

Sponsor: Tibotec Pharmaceutical Limited

Interventions telaprevir

Updated 8 times since 2017 Last updated: Feb 26, 2014 Started: Jun 30, 2009 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Hepatitis C, this trial is completed. The trial is conducted by Tibotec Pharmaceutical Limited and has accumulated 8 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tibotec Pharmaceutical Limited
Vertex Pharmaceuticals Incorporated

Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Altanta, United States , Baltimore, United States , Berlin, Germany , Birmingham, United States , Boston, United States , Chapel Hill, United States , Cincinnati, United States , Clichy, France , Cologne, Germany and 31 more locations